You are currently browsing the archives for 14 February 2015.
Displaying 1 - 2 of 2 entries.

CEO of Omni Bio.

The Diabetes Patent and other patents and patent applications that Omni Bio licenses for the treatment for the treatment of new indications with AAT. James Crapo, CEO of Omni Bio, commented, ‘We are very pleased with the grant of the patent diabetes, anti-inflammatory properties with our first type 1 diabetes clinical trial combines excited, we believe, potentially afford Omni Bio a commercial opportunity. It strengthens our belief that AAT may, by its anti-inflammatory properties to be highly effective in the treatment of diabetes and other inflammatory diseases.

Alnylam Publishes Results from Phase II GEMINI study with ALN – RSV01Alnylam Pharmaceuticals , a leading RNAi therapeutics company announced that it results from the Phase II GEMINI study in the Proceedings of published the National Academy of Sciences . This data, which presented at the presented at the International Symposium on Respiratory Viral Infections in Singapore in 2008 showed human proof of concept with an RNAi therapeutic in a randomized, double-blind, placebo-controlled study. In this study , treatment with ALN – RSV01 statistically significant antiviral activity, including a reduction in RSV infection rate and an increase in the number of persons free of infection. Free of infection.

An essential step in the development of malaria disease viagra brukere anmeldelser.

The circumsporozoite protein has been recognized as a potential target in the development of vaccines in the earlier stages of infection with malaria is concentrated viagra brukere anmeldelser . The researchers working on this project are working on a new approach that focus a range of CSP important to a critical function of the protein target. By blocking this function is to be hoped that an invasion of the parasite can be prevented in the liver, an essential step in the development of malaria disease. – ‘We think we can see the way sub-vaccines are developed through strategically targeted this critical function of the protein, to improve,’Dr. Elizabeth Nardin, said professor in the Department of Medical Parasitology at NYU Langone Medical Center. ‘Other vaccine approaches targeting CSP have extremely high antibodies to elicit hard and maintain necessary. This approach has the potential problem problem. ‘ The reason for pursuing this targeted ‘peptide protein conjugate ‘approach is based on knowledge of both the vaccine technology can be used, and the targeting of a particular malaria protein known to elicit an immune response based. CSP has already been shown to have significant protective efficacy in this area, within the RTS, the most advanced malaria vaccine candidate, now in a Phase 3 clinical trial. Conjugate vaccineser conjugate vaccines against bacterial pathogens have evolved to spread licensed pediatric vaccines by Merck acquired. ‘History has shown that vaccines can be a powerful tool against the disease may be,’said Dr. John Shiver, vice president of vaccines discovery at Merck. ‘We recognize that new methods and partnerships, such as the collaboration with MVI and NYU Langone Medical Center, are important to continue innovation in the fight against the malaria parasite. ‘ – ‘With the availability of first-generation malaria vaccine on the horizon, we are ramping up our efforts to seek out and invest in scientific approaches for malaria vaccines, which may be even more effective and could protect more people,’said Dr. Christian Loucq, director of MVI. ‘We are very pleased that one of the world largest pharmaceutical companies and a major academic medical center have testing a promising new way to defend children against malaria obligated. P.’.

The unique implant core design which maximizes graft containment volume while the aggressive fixation spikes for increased stability between the spinous process and the implant to enable.